Takeda Pharmaceutical (TAK) News Today → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Free TAK Stock Alerts $13.84 -0.35 (-2.47%) (As of 01:26 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEmpathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAEprnewswire.com - March 27 at 8:53 AMTakeda Announces Candidates for Board of Directors at Upcoming Shareholders Meetingbusinesswire.com - March 26 at 7:07 PMTakeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japanmarkets.businessinsider.com - March 26 at 9:07 AMTakeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)finance.yahoo.com - March 26 at 9:07 AMThe Leadership Development Group Releases Guide on Talent Management Strategies For Post-Milestone Growthfinance.yahoo.com - March 21 at 10:57 AMTakeda : FDA Approves SNDA For Iclusig In Adult Patients With Newly Diagnosed Ph+ ALLmarkets.businessinsider.com - March 19 at 11:52 PMTakeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALLbusinesswire.com - March 19 at 12:20 PMAdvanced Infusion Care (AIC) Now Offers Takeda's GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] and ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)]businesswire.com - March 18 at 6:12 AMTakeda Pharmaceuticals: Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South Africafinanznachrichten.de - March 15 at 3:29 PMTakeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Updatemarketbeat.com - March 14 at 3:35 PMProstate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033finance.yahoo.com - March 13 at 2:30 PMTakeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopeniafinance.yahoo.com - March 13 at 9:30 AMMercer Global Advisors Inc. ADV Grows Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - March 11 at 7:59 AM136,100 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Schonfeld Strategic Advisors LLCmarketbeat.com - March 8 at 6:26 AMQube Research & Technologies Ltd Reduces Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - March 7 at 5:51 AMTakeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwindsseekingalpha.com - March 5 at 12:38 PMFive things: Takeda's big lease, more biotech cuts, Ted Williams' jersey and a basketball bandwagonbizjournals.com - March 5 at 7:38 AMTakeda staying in Kendall Squaremsn.com - March 4 at 9:19 PMTakeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profitsseekingalpha.com - March 3 at 8:44 AMFmr LLC Buys 115,947 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - March 2 at 5:20 AMTakeda and India's Biological E. to accelerate access to dengue vaccine in endemic areasmsn.com - February 27 at 8:20 AMJapan's Takeda partners with India's Biological E. to boost dengue vaccine productionreuters.com - February 27 at 1:07 AMTakeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areasbusinesswire.com - February 26 at 11:30 PMChampioning Rare Voices on Rare Disease Dayfinance.yahoo.com - February 26 at 9:45 AMEnvestnet Asset Management Inc. Grows Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - February 26 at 5:32 AMEvaluating Johnson & Johnson Against Peers In Pharmaceuticals Industrybenzinga.com - February 24 at 7:07 PM5 Best Japanese Stocks To Buy In 2024insidermonkey.com - February 24 at 6:03 AMForbes ranks 18 Massachusetts companies among America’s best large employersmsn.com - February 21 at 3:58 PMPolpharma looks to challenge Takeda’s Entyvio in IBDmsn.com - February 21 at 3:58 PMQ4 2023 Halozyme Therapeutics Inc Earnings Callfinance.yahoo.com - February 21 at 10:33 AMDengue Rages Around The Globe. Where Are The Vaccines?forbes.com - February 20 at 8:55 AMBrandes Investment Partners LP Has $27.88 Million Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - February 19 at 1:26 PMBiguanides Market to Capture a CAGR of 2.1% While Touching Approximately USD 5.9 Billion by 2030 | MarketDigitsfinance.yahoo.com - February 19 at 12:34 AMQRG Capital Management Inc. Makes New $5.51 Million Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - February 18 at 7:39 AMFDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)finance.yahoo.com - February 12 at 1:03 PMUPDATE 2-Takeda's treatment becomes first oral therapy for esophageal condition in USfinance.yahoo.com - February 12 at 1:03 PMTakeda’s Qdenga dengue vaccine granted conditional approvalmsn.com - February 9 at 1:09 PMGood News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Studymsn.com - February 9 at 1:09 PMVan ECK Associates Corp Has $19.78 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)marketbeat.com - February 9 at 7:47 AMTakeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024finance.yahoo.com - February 8 at 9:00 PMTakeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call Presentationseekingalpha.com - February 5 at 1:23 AMCRISPR CMO who resigned after Casgevy approval lands at Takedamsn.com - February 2 at 7:56 PMProtagonist (PTGX) Up 14% on Licensing Deal With Takedafinance.yahoo.com - February 2 at 2:55 PMProtagonist Therapeutics Inks Deal with Takeda on Rusfertidemsn.com - February 2 at 4:55 AMWhy Is Japanese Drugmaker Takeda Stock Trading Lower Today?msn.com - February 1 at 5:32 PMTakeda's Q3 profits take a hit due to new generic ADHD drugsbizjournals.com - February 1 at 5:32 PMInnovationRx: Show Me The Healthcare Savingsforbes.com - February 1 at 12:31 PMTakeda and Protagonist sign rusfertide development dealmsn.com - February 1 at 12:31 PMTakeda Pharmaceutical Stock (NYSE:TAK) Dividends: History, Yield and Datesbenzinga.com - February 1 at 12:31 PMTakeda Pharmaceutical gets new CFOmsn.com - February 1 at 7:29 AM Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.) Watch my video for all of the details TAK Media Mentions By Week TAK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TAK News Sentiment▼0.650.60▲Average Medical News Sentiment TAK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TAK Articles This Week▼55▲TAK Articles Average Week Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GMAB News Today ALNY News Today BMRN News Today BGNE News Today TEVA News Today VTRS News Today KRTX News Today RDY News Today ZTS News Today SRPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TAK) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.